Positron emission tomography (PET) methods that use specific radioligands, other than FDG, are becoming available to evaluate patients with cancer. For example, choline [1] labeled with the positron emitter 11C (methyl-11C choline) has been introduced as a PET ligand to visualize various tumors, particularly those located in the pelvis, in which the background radioactivity of the tracer is low [2]. We describe a patient who had undergone prostatectomy with a progressive increase of prostate-specific antigen (PSA) levels in whom PET with methyl-11C choline was determinant in indicating the presence of bone metastatic disease.
Picchio, M., Landoni, C., Messa, M., Gianolli, L., Matarrese, M., De Cobelli, F., et al. (2002). Positive [11c]choline and negative [18F]FDG with positron emission tomography in recurrence of prostate cancer. AMERICAN JOURNAL OF ROENTGENOLOGY, 179(2), 482-484 [10.2214/ajr.179.2.1790482].
Positive [11c]choline and negative [18F]FDG with positron emission tomography in recurrence of prostate cancer
LANDONI, CLAUDIO;MESSA, MARIA CRISTINA;FAZIO, FERRUCCIO
2002
Abstract
Positron emission tomography (PET) methods that use specific radioligands, other than FDG, are becoming available to evaluate patients with cancer. For example, choline [1] labeled with the positron emitter 11C (methyl-11C choline) has been introduced as a PET ligand to visualize various tumors, particularly those located in the pelvis, in which the background radioactivity of the tracer is low [2]. We describe a patient who had undergone prostatectomy with a progressive increase of prostate-specific antigen (PSA) levels in whom PET with methyl-11C choline was determinant in indicating the presence of bone metastatic disease.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
